SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense volatility as investors closely monitor geopolitical escalations in the Middle East, specifically threats surrounding the Strait of Hormuz and potential impacts on global energy supply chains. Market participants are actively debating the sustainability of current tech valuations and discussing whether the recent pullbacks represent a strategic buying opportunity or the beginning of a deeper market correction driven by macroeconomic uncertainty.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is facing a sharp sell-off as a combination of a surging dollar, rising interest rate expectations, and broader liquidity concerns drives investors to exit precious metal positions. The community is actively debating whether this is a temporary shakeout that offers a buying opportunity for long-term holders or a more systemic shift that challenges gold's status as a traditional safe-haven asset during times of geopolitical tension.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is currently trending as investors grapple with extreme market volatility driven by escalating geopolitical tensions in the Middle East and the uncertainty surrounding impending policy deadlines. The community is sharply divided, with intense debate focused on whether these conditions signal an imminent market collapse or a temporary shakeout that will ultimately favor opportunistic buyers.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently under intense market pressure as investors weigh the impact of rising geopolitical tensions and crude oil price volatility against the company's ambitious, capital-intensive plans for in-house AI chip production. The community remains deeply divided, with bulls pointing to long-term synergies across Tesla, SpaceX, and xAI, while bears express skepticism over recent legal hurdles, ongoing delivery concerns, and the feasibility of Musk's aggressive technology roadmap.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is facing intense downward pressure driven by a combination of broader market volatility and a persistent short-seller report from Muddy Waters, which has triggered aggressive trading from both retail bulls and institutional bears. The community remains deeply divided, with many long-term investors pointing to CEO Anthony Noto’s recent insider buying as a signal of fundamental strength, while bears emphasize the ongoing uncertainty surrounding the firm’s accounting practices and macro-economic headwinds.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is facing downward pressure as investors express skepticism over the company's massive capital expenditures toward AI infrastructure and the recent decision to scale back its metaverse initiatives. Community sentiment is deeply divided, with some traders bracing for further volatility due to technical chart patterns and layoff rumors, while long-term investors maintain conviction in the stock's underlying fundamentals and growth potential.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is trending as investors weigh the impact of rising geopolitical tensions and inflationary pressures on the junior gold miners sector. Community sentiment remains split between bullish bets on gold as a hedge against systemic risk and bearish warnings about the volatility and leverage inherent in the instrument.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest a major breakthrough in EUV light source technology that could significantly boost chip production efficiency by 2030, alongside anticipation for upcoming earnings. The community remains focused on the company's long-term dominance as an essential 'pick and shovel' play for the ongoing AI infrastructure build-out.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing significant downward pressure following its post-earnings rally, as investors grapple with broader geopolitical instability and concerns over high infrastructure spending. While the community remains deeply divided between those viewing the pullback as a strategic accumulation opportunity based on strong backlog growth and those concerned by persistent selling and technical weakness, sentiment is heavily influenced by intense debates over AI's long-term profitability versus potential overvaluation.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

United States Natural Gas Fund (UNG) is trending as traders navigate extreme volatility fueled by severe winter weather, supply disruptions, and significant geopolitical tensions in the Middle East. The community is actively debating the sustainability of these price spikes, with many weighing the impact of weather-driven demand against the potential for rapid supply normalization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pressure Mounts on U.S. Consumers Amid Middle East Conflict: ETFs to Watch

Middle East tensions and rising oil prices are weighing on U.S. consumers, dragging down confidence and pushing investors toward defensive ETFs.

Middle East Turmoil and U.S. Debt Surge: ETFs in Focus

With U.S. budget deficits and already elevated debt, the ongoing Middle East war could worsen the fiscal outlook, making defensive ETF strategies worth considering for stability.

XLV, UNH, TMO, PFE: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have...

<ul class="summary-bullets"><li>The clinical trial included 36 participants who continued taking existing medications for generalized anxiety disorder while receiving HLP004 injections.</li><li>Researchers administered two doses three weeks apart and monitored participants for 12 weeks.</li><li>Six months after treatment, about 67% of the combined study group met the criteria for a clinical response.</li></ul>Helus Pharma (HELP) announced encouraging early-stage clinical results for its experimental anxiety treatment HLP004 on Thursday, reporting notable symptom improvement among patients with moderate-to-severe generalized anxiety disorder.&nbsp;The clinical-stage drug developer said its Phase 2 signal detection trial showed statistically meaningful improvements when the therapy was used alongside standard antidepressant treatments.&nbsp;<h2 class="st-heading-2">Trial Demonstrates Significant Anxiety Reduction</h2>In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks.&nbsp;The clinical trial included 36 participants who continued taking existing medications for generalized anxiety disorder while receiving HLP004 injections. Researchers administered two doses, three weeks apart, and monitored participants for 12 weeks, with additional follow-up planned for up to 1 year.<a href="https://stocktwits.com/symbol/HELP">Helus Pharma stock</a> traded over 22% lower in Thursday’s remarket.&nbsp;<h2 class="st-heading-2">Long-Lasting Response Observed In Many Patients</h2>The company also reported sustained benefits beyond the initial treatment period. Six months after treatment, about 67% of the combined study group met the criteria for a clinical response, while 39% reached remission.Among those receiving the higher 20-milligram dose, 59% showed improvement and 32% achieved remission after six weeks. In the lower-dose group, about 30% of patients met response and remission benchmarks at the same time point.<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>Despite the stock’s decline in the premarket session, retail sentiment on Stocktwits around the stock flipped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_083359_png_25a9744605.webp" alt="HELP’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="925" height="96"><figcaption>HELP’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they have bought the dip.&nbsp;<stembedurl>https://stocktwits.com/Jimbob3016/message/646658779</stembedurl>HELP stock has gained over 4% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/liquidia-stock-gains-premarket-on-q4-revenue-beat-investors-are-betting-on-yutrepia-growth/cZdQrwNRI33">Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism

In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks. 

Equity

In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks. 


<ul class="summary-bullets"><li>Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4.</li><li>The company recorded net income of $18 million during the quarter, compared to an $81 million loss during the year-ago period.</li><li>Selling, general, and administrative expenses fell 53% year-over-year.&nbsp;</li></ul>Novavax, Inc. (NVAX) reported a sharp increase in fourth-quarter (Q4) and 2025 revenue as the vaccine maker leaned on partnership income, cost cuts and product sales.The Maryland-based biotech generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. Both the metrics surpassed the analysts’ consensus estimates of $90.26 million and a loss of $0.55, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Q4 Performance Highlights</h2>Annual revenue surged 65% YoY to $1.12 billion, driven in large part by $625 million in Nuvaxovid sales linked primarily to settlements of earlier advance purchase deals.Quarterly product sales totaled $39 million, while full-year product sales rose to $685 million. Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4 and $386 million for the year. The company said it earned $225 million in milestones from the Sanofi collaboration in 2025.<blockquote>"In 2025, we made significant progress on our corporate strategy, marked with the successful achievement of key milestones under our Sanofi agreement, progress towards potential new partnerships, in the form of multiple MTAs signed with other parties enabling experimentation with our Matrix-M adjuvant technology and the advancement of our own R&amp;D efforts.”-John C. Jacobs, President and CEO, Novavax</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax stock</a> traded over 1% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;&nbsp;<h2 class="st-heading-2">Costs Fall As Profitability Improves</h2>Novavax reduced its cost of sales to $22 million in the fourth quarter from $37 million a year earlier. The decline followed the divestiture of its Czech manufacturing site and lower overhead and inventory-related charges.Selling, general, and administrative expenses fell more than half YoY as commercial responsibilities transitioned to Sanofi and infrastructure was streamlined. The company recorded net income of $18 million in Q4, compared to an $81 million loss during the year-ago period. Novavax ended 2025 with $751 million in cash and equivalents.&nbsp;NVAX stock has gained ovr 0% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-falls-premarket-es8-demand-powers-through-chip-shortage/cZTG3ncRIbK">Nio Stock Falls Premarket: Flagship ES8 Demand Powers Through Fresh Chip Shortage Disruption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue 

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

<ul class="summary-bullets"><li>PROCEPT BioRobotics’ Q4 revenue of $76.4 million and loss per share of $0.53 both missed street estimates.&nbsp;</li><li>According to Bank of America, in Q4, PROCEPT BioRobotics delivered results that fell short of analyst forecasts by 18.5%.</li><li>The firm indicated that the latest quarterly update failed to ease concerns about execution and financial momentum.</li></ul>Bank of America has downgraded PROCEPT BioRobotics Corp. (PRCT) shares, citing mounting concerns about earnings visibility and profitability, reflecting skepticism about the company’s near-term performance as it navigates widening losses.In the fourth quarter (Q4), the company reported a revenue of $76.4 million, a 12% year-over-year (YoY) increase, and a loss per share (EPS) of $0.53. Both the financial metrics were below the analysts’ consensus estimates of $93.70 million and a loss of $0.31, respectively, according to Fiscal AI data.&nbsp;<a href="https://stocktwits.com/symbol/PRCT">PROCEPT BioRobotics’ stock</a> traded over 28% lower in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">BofA Flags Profitability Concerns</h2>Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’ and slashed its price target to $20 from $38, according to TheFly. The firm flagged fresh doubts following the company’s Q4 earnings discussion, noting uncertainty about whether management can meet Wall Street’s projections.&nbsp;Bank of America indicated that the latest quarterly update failed to ease concerns about execution and financial momentum.According to Bank of America, in Q4, PROCEPT BioRobotics delivered results that fell short of analyst forecasts by 18.5%. The shortfall coincides with a shift in the company’s longstanding approach to offering volume-based discounts to customers. At the same time, management has undertaken a reorganization of its sales team, adding another layer of transition risk.The firm emphasized that the company remains unprofitable, with operating losses deepening after the latest earnings. That trend, Bank of America argued, constrains the stock’s valuation and limits potential upside in the near term.&nbsp;<h2 class="st-heading-2">Retail Traders Remain Bullish Despite Selloff</h2>However, on Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume flipped to ‘extremely high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_26_055954_png_4ab610861f.webp" alt="PRCT’s Sentiment Meter and Message Volume as of 05:30 a.m. ET on Feb. 26, 2026 | Source: Stocktwits" width="933" height="101"><figcaption>PRCT’s Sentiment Meter and Message Volume as of 05:30 a.m. ET on Feb. 26, 2026 | Source: Stocktwits</figcaption></figure>PRCT stock has declined by over 59% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-falls-premarket-es8-demand-powers-through-chip-shortage/cZTG3ncRIbK">Nio Stock Falls Premarket: Flagship ES8 Demand Powers Through Fresh Chip Shortage Disruption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the PROCEPT BioRobotics Corporation logo is seen displayed on a smartphone screen.

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’. 

<ul class="summary-bullets"><li>As a result of the delisting decision, CASI’s shares will be suspended for trading at the opening of business on Thursday.</li><li>The company stated that it does not intend to review the Nasdaq’s delisting decision.</li><li>CASI stated in its announcement that it expects the company's existing shares to be traded on the over-the-counter market operated by OTC Markets Group Inc.</li></ul>CASI Pharmaceuticals Inc. (CASI) shares tanked more than 64% in Wednesday’s opening trade after the company announced that it had received a delisting decision from the Nasdaq.CASI stated that the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.As a result of the delisting decision, CASI’s shares will be suspended for trading at the opening of business on Thursday. The company stated that it does not intend to review the Nasdaq’s delisting decision.CASI had received an extension in December 2025 to comply with the Nasdaq’s Market Value of Listed Securities (MVLS) Rule 5550(b)(2) by Feb. 17, 2026.The MVLS rule requires a company’s market capitalization to be above $35 million for 30 consecutive trading days.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CASI">CASI Pharmaceuticals</a> trended in the ‘bullish’ territory.<h2 class="st-heading-2">Where Will CASI’s Existing Shares Be Traded Now?</h2>CASI stated in its announcement that it expects the company's existing shares to be traded on the over-the-counter market operated by OTC Markets Group Inc.However, the company said there is no guarantee that this will materialize.“The delisting from Nasdaq will have no significant impact on the Company's operations,” the company said.<h2 class="st-heading-2">What Does CASI Do?</h2>CASI is a San Francisco, California-based biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for the treatment of organ transplant rejection and autoimmune diseases.In January, CASI announced additional data from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia (ITP). The company stated that CID-103 demonstrated a manageable safety profile, with only two Grade 3 treatment-related events and no dose-limiting toxicities.Grade 3 treatment-related events are severe and medically significant, but not life-threatening adverse events.<a href="https://stocktwits.com/symbol/CASI">CASI stock</a> is down 66% year-to-date and 87% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-soars-pre-market-on-q4-beat-recursion-reached-inflection-point/cZRy27nR46D">RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low?

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

<ul class="summary-bullets"><li>The reverse split will consolidate every 30 existing shares into one new share.</li><li>The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.</li><li>After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million.</li></ul>Incannex Healthcare Inc. (IXHL) announced on Wednesday that its board of directors has approved a 1-for-30 reverse stock split, which was previously approved by shareholders at a special meeting on May 27, 2025.The reverse split is set to take legal effect at 4:01 p.m. ET on Feb. 26, 2026.<h2 class="st-heading-2">Purpose And Impact Of The Split</h2>Following this adjustment, Incannex Healthcare common shares will begin trading on The Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’.The reverse split will consolidate every 30 existing shares into one new share, aiming to raise the per-share market price. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements and maintain continued listing eligibility.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/IXHL">Incannex stock</a> tumbled over 32% on Wednesday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Share Structure And Equity Adjustments</h2>Incannex said that&nbsp;no fractional shares will be issued, and shareholders entitled to fractional amounts will receive an additional share to round up to a whole unit.&nbsp;After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million, although the total number of authorized shares will remain unchanged. Existing equity awards and stock incentive plans will see proportional adjustments in both share numbers and exercise prices to reflect the split.&nbsp;In January, Incannex said it is entering 2026 with over $70 million in cash, following a $12.5 million private placement financing and the elimination of legacy Series A warrants. The company also authorized a $20 million share repurchase program.IXHL stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q4-earnings-today-retail-says-pressure-is-worse-this-time/cZRy3JBRIG4">Nvidia Q4 Earnings Today – Retail Says 'Pressure Is Worse This Time’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background.

Why Did IXHL Stock Tank Over 32% Today? 

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 


<ul class="summary-bullets"><li>The therapy is to treat adults and children with Friedreich’s ataxia, a progressive neurodegenerative disorder.</li><li>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;</li><li>FDA agreed that skin FXN could serve as a novel surrogate endpoint, supporting the planned Biologics License Application submission.</li></ul>Larimar Therapeutics, Inc. (LRMR) announced on Tuesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its frataxin (FXN) protein replacement therapy, nomlabofusp.&nbsp;The therapy is to treat adults and children with Friedreich’s ataxia (FA), a progressive neurodegenerative disorder causing nervous system damage.<h2 class="st-heading-2">FDA Endorses Skin FXN As Surrogate Endpoint</h2>The FDA’s decision follows encouraging clinical data from Larimar’s ongoing open-label study and a recent Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program meeting.&nbsp;The agency also agreed that skin FXN could serve as a novel surrogate endpoint reasonably likely to predict clinical benefit, supporting the planned Biologics License Application (BLA) submission targeted for June 2026. The FDA additionally confirmed that the planned analyses, reference population, and clinical endpoints are aligned with BLA requirements.Following the FDA’s decision,&nbsp;<a href="https://stocktwits.com/symbol/LRMR">Larimar stock</a> traded over 30% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_24_084542_png_18caaedccf.webp" alt="LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Encouraging Clinical Data</h2>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;Improvements were seen across four key clinical measures, the modified Friedreich Ataxia Rating Scale (mFARS), FARS-Activities of Daily Living (ADL), 9-Hole Peg Test (9-HPT), and Modified Fatigue Impact Scale (MFIS) after one year of treatment.&nbsp;The results suggest that nomlabofusp could slow or reverse FA progression compared with the natural disease course observed in the Friedrich’s Ataxia Clinical Outcomes Measure Study (FACOMS).LRMR stock declined by over 7% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intuit-stock-rallies-pre-market-today-anthropic-connection/cZRvyjtR4C7">Intuit Stock Rallies Pre-Market Today And There’s An Anthropic Connection</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? 

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

<ul class="summary-bullets"><li>McCutcheon said findings presented for VIR-5500 surpassed expectations and strengthened Vir’s standing among therapies in prostate cancer.</li><li>He noted that the results bolster confidence in Vir’s PRO-XTEN platform and add support to the company’s outlook for its hepatitis D regimen.</li><li>Morgan Stanley analyst Michael Ulz increased his price target on Vir to $24 from $20.</li></ul>Vir Biotechnology Inc. (VIR) received a pair of bullish calls from Wall Street after unveiling fresh clinical data and a sizable new drug partnership, prompting analysts to raise their ratings and price targets on the stock.On Monday, the company reported strong fourth-quarter earnings and encouraging Phase 1 results for its cancer therapy study.&nbsp;<h2 class="st-heading-2">Raymond James Upgrades Vir Biotechnology</h2>Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12 following the series of corporate updates, according to TheFly.&nbsp;According to McCutcheon, findings presented for VIR-5500 surpassed expectations and strengthened its standing among PSMA-directed T-cell engager therapies in prostate cancer.He noted that the results bolster confidence in Vir’s PRO-XTEN platform and add support to the company’s outlook for its hepatitis D regimen combining tobevibart and elebsiran, which he believes has a viable regulatory path.<a href="https://stocktwits.com/symbol/VIR">Vir Biotechnology stock</a> traded over 60% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_24_071715_png_bf610d177d.webp" alt="VIR’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits" width="926" height="103"><figcaption>VIR’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure>Separately, Morgan Stanley analyst Michael Ulz increased his price target on Vir to $24 from $20 while maintaining an ‘Overweight’ rating. Ulz said early-stage data for VIR-5500 reinforce its potential to emerge as a leading treatment option in prostate cancer.<h2 class="st-heading-2">New Partnership Adds Financial Backing</h2>Vir also announced a collaboration with Astellas Pharma that includes $335 million in upfront and near-term payments. The agreement outlines a 50/50 profit split in the U.S. and royalty payments on sales outside the country, providing additional capital and shared commercialization support.The partnership will co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues.&nbsp;Vir is eligible to earn up to $1.37 billion in additional development, regulatory, and sales milestones.VIR stock has declined by over 21% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-is-bringing-mac-mini-production-to-texas-now/cZRvveYR4zD">Apple Is Bringing Mac Mini Production To Texas Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Vir Biotechnology logo is seen on a smartphone and a computer screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLV News

XLVHealth Care Select Sector SPDR Fund